<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Pricing</title>
	<atom:link href="http://www.tapanray.in/tag/pricing/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Focus On All 3 Areas of Innovation For Affordable Access To Innovative Drugs</title>
		<link>http://www.tapanray.in/focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs</link>
		<comments>http://www.tapanray.in/focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs/#comments</comments>
		<pubDate>Mon, 29 Nov 2021 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[ace]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[differential]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[Models]]></category>
		<category><![CDATA[outcomesbusiness]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[problem]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[three areas]]></category>
		<category><![CDATA[tiered]]></category>
		<category><![CDATA[win-win]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10615</guid>
		<description><![CDATA[Medical treatment has made astonishing advances over the years. But the packaging and delivery of that treatment are often inefficient, ineffective, and consumer unfriendly. This was articulated in an article on innovation in healthcare, published in the Harvard Business Review, way &#8230; <a href="http://www.tapanray.in/focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/focus-on-all-3-areas-of-innovation-for-affordable-access-to-innovative-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Covid 2.0 Rampages India As Top Echelon Policy Makers Ignore Science</title>
		<link>http://www.tapanray.in/covid-2-0-rampages-india-as-top-echelon-policy-makers-ignore-science/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=covid-2-0-rampages-india-as-top-echelon-policy-makers-ignore-science</link>
		<comments>http://www.tapanray.in/covid-2-0-rampages-india-as-top-echelon-policy-makers-ignore-science/#comments</comments>
		<pubDate>Mon, 26 Apr 2021 00:00:54 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[appropriate]]></category>
		<category><![CDATA[beds]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Country]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[Covid 2.0]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[dilemmas]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[misgivings]]></category>
		<category><![CDATA[MIT]]></category>
		<category><![CDATA[nation]]></category>
		<category><![CDATA[overwhelmed]]></category>
		<category><![CDATA[Oxygen]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[rampage]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[remdesivir]]></category>
		<category><![CDATA[shortage]]></category>
		<category><![CDATA[side-effects]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10482</guid>
		<description><![CDATA[‘India is in the endgame of COVID,’ announced the union health minister of India, just in the last month – March 08, 2021. Although, it was then clearly known to medical fraternity that today’s Covid vaccines won’t be magic bullets against rapidly &#8230; <a href="http://www.tapanray.in/covid-2-0-rampages-india-as-top-echelon-policy-makers-ignore-science/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/covid-2-0-rampages-india-as-top-echelon-policy-makers-ignore-science/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Neutralize Covid-19 Impact on Drug Prices And Market Access For Faster Recovery</title>
		<link>http://www.tapanray.in/neutralize-covid-19-impact-on-drug-prices-and-market-access-for-faster-recovery/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=neutralize-covid-19-impact-on-drug-prices-and-market-access-for-faster-recovery</link>
		<comments>http://www.tapanray.in/neutralize-covid-19-impact-on-drug-prices-and-market-access-for-faster-recovery/#comments</comments>
		<pubDate>Mon, 14 Sep 2020 00:00:02 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[assessment]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Eldorado]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[fair]]></category>
		<category><![CDATA[fair drug pricing]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HTA]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Models]]></category>
		<category><![CDATA[neutralize]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[resources]]></category>
		<category><![CDATA[sensitivity]]></category>
		<category><![CDATA[spending]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10259</guid>
		<description><![CDATA[Covid-19 pandemic that has not spared any facet of human lives and livelihoods, has also reignited several ongoing debates related to the drug industry. The need to urgently resolve these issues grows manifold, as the real magnitude of this health &#8230; <a href="http://www.tapanray.in/neutralize-covid-19-impact-on-drug-prices-and-market-access-for-faster-recovery/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/neutralize-covid-19-impact-on-drug-prices-and-market-access-for-faster-recovery/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Covid-19 Drugs: Accessibility, Affordability And Availability</title>
		<link>http://www.tapanray.in/covid-19-drugs-accessibility-affordability-and-availability/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=covid-19-drugs-accessibility-affordability-and-availability</link>
		<comments>http://www.tapanray.in/covid-19-drugs-accessibility-affordability-and-availability/#comments</comments>
		<pubDate>Mon, 27 Jul 2020 00:00:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[accessibility]]></category>
		<category><![CDATA[affordable affordability]]></category>
		<category><![CDATA[Availability]]></category>
		<category><![CDATA[available]]></category>
		<category><![CDATA[catastrophe]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[emergency]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[manufacturers]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[skepticism]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10198</guid>
		<description><![CDATA[Covid-19 continues refusing to unravel the key to neutralize its destructive power &#8211; for bringing human life and the socioeconomic fabric of a country back to the old normal again. Just as India, all other countries are, apparently, awaiting a &#8230; <a href="http://www.tapanray.in/covid-19-drugs-accessibility-affordability-and-availability/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/covid-19-drugs-accessibility-affordability-and-availability/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Setting A Cost Of Time That Patients May Gain From A New Therapy</title>
		<link>http://www.tapanray.in/setting-a-cost-of-time-that-patients-may-gain-from-a-new-therapy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=setting-a-cost-of-time-that-patients-may-gain-from-a-new-therapy</link>
		<comments>http://www.tapanray.in/setting-a-cost-of-time-that-patients-may-gain-from-a-new-therapy/#comments</comments>
		<pubDate>Mon, 16 Mar 2020 00:00:07 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[biopharma]]></category>
		<category><![CDATA[calculation]]></category>
		<category><![CDATA[calculator]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cost of time]]></category>
		<category><![CDATA[economics]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[prolonging]]></category>
		<category><![CDATA[quality of life]]></category>
		<category><![CDATA[quantity of life]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rare diseases]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[setting]]></category>
		<category><![CDATA[Spiranza]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thicket]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[years]]></category>
		<category><![CDATA[Zolgensma]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9916</guid>
		<description><![CDATA[Since quite some, an intense ongoing debate about setting a cost of time, often by a few months, that patients could possibly gain from a new therapy for complex diseases. The answer still remains elusive.  Meanwhile, newer therapies for treating cancer, &#8230; <a href="http://www.tapanray.in/setting-a-cost-of-time-that-patients-may-gain-from-a-new-therapy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/setting-a-cost-of-time-that-patients-may-gain-from-a-new-therapy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Reaping Rich Harvest With Orphan Drugs</title>
		<link>http://www.tapanray.in/reaping-rich-harvest-with-orphan-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=reaping-rich-harvest-with-orphan-drugs</link>
		<comments>http://www.tapanray.in/reaping-rich-harvest-with-orphan-drugs/#comments</comments>
		<pubDate>Mon, 21 Oct 2019 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[groups]]></category>
		<category><![CDATA[health for all]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Orphan]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[performance]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[quid pro quo]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reaping]]></category>
		<category><![CDATA[rich harvest]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9752</guid>
		<description><![CDATA[A set of perplexing questions on the drug industry has been haunting many, since long. One such area is intimately associated with the core purpose of this business, as enunciated by each company, often publicly. Just to give a feel &#8230; <a href="http://www.tapanray.in/reaping-rich-harvest-with-orphan-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/reaping-rich-harvest-with-orphan-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dynamics of Cancer Therapy Segment Remain Enigmatic</title>
		<link>http://www.tapanray.in/dynamics-of-cancer-therapy-segment-remain-enigmatic/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=dynamics-of-cancer-therapy-segment-remain-enigmatic</link>
		<comments>http://www.tapanray.in/dynamics-of-cancer-therapy-segment-remain-enigmatic/#comments</comments>
		<pubDate>Mon, 14 Oct 2019 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Assistance]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[day]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[enigma]]></category>
		<category><![CDATA[enigmatic]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[PAP]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[program]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[segment]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[UICC]]></category>
		<category><![CDATA[Union for International Cancer Control]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9745</guid>
		<description><![CDATA[Currently, cancer is likely to occupy the center stage on any discussion related to the fastest growing therapy segments in the pharma or biotech industries. There are several reasons behind such probability, some of which include: Cancer is not only &#8230; <a href="http://www.tapanray.in/dynamics-of-cancer-therapy-segment-remain-enigmatic/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/dynamics-of-cancer-therapy-segment-remain-enigmatic/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Continues ‘The Cat And Mouse Game’ In Pharma Business?</title>
		<link>http://www.tapanray.in/continues-the-cat-and-mouse-game-in-pharma-business/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=continues-the-cat-and-mouse-game-in-pharma-business</link>
		<comments>http://www.tapanray.in/continues-the-cat-and-mouse-game-in-pharma-business/#comments</comments>
		<pubDate>Mon, 24 Jun 2019 00:00:55 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Americans]]></category>
		<category><![CDATA[anti-trust]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[cat]]></category>
		<category><![CDATA[cat and mouse game]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[competitive]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[evade]]></category>
		<category><![CDATA[fixing]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[lawsuit]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[mouse]]></category>
		<category><![CDATA[ooff the cuff]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[price-fixing]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[wrongdoing]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9601</guid>
		<description><![CDATA[Many are already aware of the critical factors that make generic drugs so important for patients &#8211; virtually for all. These don’t just facilitate greater access to health care &#8211; offering affordable alternatives to high-priced off-patent innovative drugs. This is &#8230; <a href="http://www.tapanray.in/continues-the-cat-and-mouse-game-in-pharma-business/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/continues-the-cat-and-mouse-game-in-pharma-business/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>How Creative Is Pharma Industry?</title>
		<link>http://www.tapanray.in/how-creative-is-pharma-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=how-creative-is-pharma-industry</link>
		<comments>http://www.tapanray.in/how-creative-is-pharma-industry/#comments</comments>
		<pubDate>Mon, 15 Apr 2019 00:00:57 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[creative]]></category>
		<category><![CDATA[creativity]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[gross]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[inclusive]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[invention]]></category>
		<category><![CDATA[margin]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[mother]]></category>
		<category><![CDATA[necessity]]></category>
		<category><![CDATA[Operating]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[revenue]]></category>
		<category><![CDATA[ROI]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[trust]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9482</guid>
		<description><![CDATA[“Because the purpose of business is to create a customer, the business enterprise has two – and only two – basic functions: marketing and innovation. Marketing and innovation produce results; all the rest are costs. Marketing is the distinguishing, unique &#8230; <a href="http://www.tapanray.in/how-creative-is-pharma-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/how-creative-is-pharma-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Innovative ‘Medicines Too Damn Expensive’: Health Risk For Billions of People</title>
		<link>http://www.tapanray.in/innovative-medicines-too-damn-expensive-health-risk-for-billions-of-people/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=innovative-medicines-too-damn-expensive-health-risk-for-billions-of-people</link>
		<comments>http://www.tapanray.in/innovative-medicines-too-damn-expensive-health-risk-for-billions-of-people/#comments</comments>
		<pubDate>Mon, 18 Mar 2019 00:00:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[ailments]]></category>
		<category><![CDATA[arbitrary]]></category>
		<category><![CDATA[billions]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[damn]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[expensive]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[life-saving]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[millions]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[Too]]></category>
		<category><![CDATA[transparency]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9448</guid>
		<description><![CDATA[Most ‘medicines are too damn expensive. And a key part of the problem is the lack of consistent information about drug pricing. It’s not often that the Trump administration and the anti-poverty NGO Oxfam find themselves singing from the same &#8230; <a href="http://www.tapanray.in/innovative-medicines-too-damn-expensive-health-risk-for-billions-of-people/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/innovative-medicines-too-damn-expensive-health-risk-for-billions-of-people/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
